Conference call regarding Elekta’s Q2 report for 2018/19

STOCKHOLM, November 16, 2018 – Elekta (EKTA-B.ST) will publish its Q2 report for 2018/19 on November 29, as per:

  • The report will be published at 07:30 CET
  • Elekta will host a telephone conference starting at 10:00 CET with Richard Hausmann, President and CEO, and Gustaf Salford, CFO.

To take part in the conference call, please dial in about five minutes in advance.

  • UK dial-in number: +44 (0) 203 008 9804 
  • US dial-in number: +1 855 831 5944
  • Swedish dial-in number: +46 (0) 8 566 426 92 

The telephone conference will also be broadcasted live online, through the following link (however, in order to ask questions, it is necessary to call in):
http://event.on24.com/wcc/r/1864250-1/A24354D1B35F867BA3C529080E0D4B3C

# # #

For further information, please contact:
Oskar Bosson, Global EVP Corporate Communications and Investor Relations
Tel: +46 70 410 7180, E-mail: Oskar.Bosson@elekta.com
Time zone: CET: Central European Time

Gunilla Öhman, Head of Investor Relations (interim)
Tel: +46 70 763 8125, E-mail: gunilla.oehman@elekta.com
Time zone: CET: Central European Time

 About Elekta
Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,700 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm. www.elekta.com

Tags:

About Us

For almost five decades, Elekta has been a leader in precision radiation medicine. Our nearly 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.

Subscribe

Documents & Links